87 related articles for article (PubMed ID: 7295487)
1. Human platelet function as a model for investigating the clinical efficacy of chlorpromazine.
Youdim MB; Hefez A; Oppenheim B
Br J Clin Pharmacol; 1981 Oct; 12(4):535-42. PubMed ID: 7295487
[TBL] [Abstract][Full Text] [Related]
2. Serotonin receptor site in human platelets from control and chlorpromazine treated subjects.
Oppenheim B; Hefez A; Youdim MB
Prog Biochem Pharmacol; 1980; 16():119-32. PubMed ID: 7443729
[TBL] [Abstract][Full Text] [Related]
3. Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine.
Boullin DJ; Woods HF; Grimes RP; Grahame-Smith DG
Br J Clin Pharmacol; 1975 Feb; 2(1):29-35. PubMed ID: 791316
[TBL] [Abstract][Full Text] [Related]
4. Resuspension of platelets: enhanced 5-hydroxytryptamine-induced aggregation in chlorpromazine treated patients due to changes in platelet properties.
Boullin DJ; Grahame-Smith DG; Grimes RP; Woods HF
Br J Clin Pharmacol; 1975 Feb; 2(1):37-9. PubMed ID: 791317
[TBL] [Abstract][Full Text] [Related]
5. Increased platelet aggregation in patients receiving chlorpromazine: responses to 5-hydroxytryptamine, dopamine and N-dimethyl dopamine.
Boullin DJ; Grimes RP
Br J Clin Pharmacol; 1976 Aug; 3(4):649-53. PubMed ID: 22216508
[TBL] [Abstract][Full Text] [Related]
6. The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients.
Orr MW; Knox JM; Allen R; Gelder MG; Grahame-Smith DG
Br J Clin Pharmacol; 1981 Mar; 11(3):255-9. PubMed ID: 6111333
[TBL] [Abstract][Full Text] [Related]
7. Effects of chlorpromazine on serotonin uptake in blood platelets.
Arora RC; Meltzer HY
Psychiatry Res; 1983 May; 9(1):23-8. PubMed ID: 6577481
[TBL] [Abstract][Full Text] [Related]
8. Effects of aspirin and prostaglandin E2 on secondary phase aggregation responses of schizophrenic patients treated with chlorpromazine.
Boullin DJ; Orr MW
Br J Clin Pharmacol; 1976 Oct; 3(5):929-33. PubMed ID: 973989
[TBL] [Abstract][Full Text] [Related]
9. Platelet aggregation and chlorpromazine therapy.
Boullin DJ; Know JM; Peters JR; Orr MW; Gelder MG; Grahame-Smith DG
Br J Clin Pharmacol; 1978 Dec; 6(6):538-40. PubMed ID: 728326
[No Abstract] [Full Text] [Related]
10. The ralationship between changes in 5-HT induced platelet aggregation and clinical state in patients treated with fluphenazine.
Orr MW; Boullin DJ
Br J Clin Pharmacol; 1976 Oct; 3(5):925-8. PubMed ID: 973988
[TBL] [Abstract][Full Text] [Related]
11. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine.
Lieberman JA; Phillips M; Gu H; Stroup S; Zhang P; Kong L; Ji Z; Koch G; Hamer RM
Neuropsychopharmacology; 2003 May; 28(5):995-1003. PubMed ID: 12700715
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the anti-dopamine D₂ and anti-serotonin 5-HT(2A) activities of chlorpromazine, bromperidol, haloperidol and second-generation antipsychotics parent compounds and metabolites thereof.
Suzuki H; Gen K; Inoue Y
J Psychopharmacol; 2013 Apr; 27(4):396-400. PubMed ID: 23427194
[TBL] [Abstract][Full Text] [Related]
13. Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial.
Lal S; Thavundayil JX; Nair NP; Annable L; Ng Ying Kin NM; Gabriel A; Schwartz G
J Psychiatry Neurosci; 2006 Jul; 31(4):271-9. PubMed ID: 16862245
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites.
Boullin DJ; Grahame-Smith DG; Grimes RP; Woods HF
Br J Pharmacol; 1975 Jan; 53(1):121-5. PubMed ID: 1125484
[TBL] [Abstract][Full Text] [Related]
15. Increases in aggregation by and uptake of 5-hydroxytryptamine with platelets from rabbits treated with chlorpromazine.
Baldacci M; Baldacci M; Bergel TD; Born GV; Hickman M
Br J Pharmacol; 1980 May; 69(1):113-8. PubMed ID: 7378650
[TBL] [Abstract][Full Text] [Related]
16. Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response.
Meltzer HY; Busch DA; Fang VS
Psychiatry Res; 1983 Aug; 9(4):271-83. PubMed ID: 6580660
[TBL] [Abstract][Full Text] [Related]
17. The reliability of 5-hydroxytryptamine induced platelet aggregation responses in schizophrenic patients treated with neuroleptic drugs.
Knox JM; Orr MW; Allen R; Gelder MG; Grahame-Smith DG
Br J Clin Pharmacol; 1981 Mar; 11(3):261-3. PubMed ID: 6111334
[TBL] [Abstract][Full Text] [Related]
18. Characterization of receptors mediating 5-hydroxytryptamine- and catecholamine-induced platelet aggregation, assessed by the actions of alpha- and beta-blockers, butyrophenones, 5-HT antagonists and chlorpromazine.
Boullin DJ; Glenton PA
Br J Pharmacol; 1978 Apr; 62(4):537-42. PubMed ID: 26445
[TBL] [Abstract][Full Text] [Related]
19. Arachidonate metabolism, 5-hydroxytryptamine release and aggregation in human platelets activated by palmitaldehyde acetal phosphatidic acid.
Brammer JP; Maguire MH
Br J Pharmacol; 1984 May; 82(1):61-72. PubMed ID: 6428500
[TBL] [Abstract][Full Text] [Related]
20. Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine.
Wode-Helgodt B; Borg S; Fyrö B; Sedvall G
Acta Psychiatr Scand; 1978 Aug; 58(2):149-73. PubMed ID: 358755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
